Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

NCT01581658 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI10773
DRUG: BI10773
DRUG: BI10773
DRUG: BI10773

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]